Ann Arbor-based Micro-Tech Endoscopy has partnered with Massachusetts’ Interscope to distribute Interscope’s EndoRotor System for interventional gastroenterology. Gastroenterology is the branch of medicine that deals with disorders of the stomach and intestines.
Interscope pioneers minimally invasive interventional endoscopic techniques designed to promote procedural solutions and cost-of-care efficiencies. It created the EndoRotor System.
“Micro-Tech’s position as a market disruptor with strong leadership provides significant scale to the Interscope team,” says Jeffery Ryan, co-founder, president, and CEO of Interscope. Ryan also said the partnership would get the device to physicians faster.
The extended clearance makes the EndoRotor the first device cleared by the U.S. Food and Drug Administration used in direct endoscopic necrosectomy, a minimally invasive technique for the treatment of infected walled-off pancreatic necrosis (necrosis is the death of body tissue due to too little blood flow) and infected pseudocysts (pseudocysts are false cysts that form when the cells of the pancreas become inflamed or are injured).
“We want to thank the hospitals, clinicians, and staff who were involved in our recent clinical trial, as well as those who contributed to our real-world data collection,” Ryan says.
Micro-Tech was founded in 2000 and creates products for endoscopic diagnosis and therapeutic medical devices. Along with the U.S., it has operations in Asia and Europe.
